Sarepta Therapeutics CEO Douglas Ingram has decided to step down by the end of 2026 or upon the appointment of his replacement, the company said in a regulatory filing.
Vinay Prasad, a senior regulator at the US Food and Drug Administration, has stepped down from his position amid controversy over the agency’s handling of Sarepta Therapeutics Inc.’s gene therapy.
26 Feb 2026-14:32
30 Jul 2025-11:29
